Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06418711 Not yet recruiting - Clinical trials for Mycobacterium Infections, Nontuberculous

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

ICoN-1
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to Guideline-based therapy (GBT).

NCT ID: NCT06417983 Not yet recruiting - Fungal Infection Clinical Trials

Topical Application of Essential Oils to Treat Onchomycosis

NailFungus
Start date: May 30, 2024
Phase:
Study type: Observational

Patients with documented onychomycosis of one or more toe nails will be treated with a daily application of a topical lacquer containing several essential oils.

NCT ID: NCT06416267 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)

MBL RiskConseq
Start date: August 2024
Phase:
Study type: Observational

The aim of this proposal is to identify immune biomarkers, genetic risk, and the clinical consequences of low count monoclonal B-cell lymphocytosis (LC MBL), a common premalignant condition affecting up to 17% of European adults age>40. LC MBL is a precursor to chronic lymphocytic leukemia (CLL), characterized by a circulating population of clonal B-cells. It is relatively understudied, despite emerging evidence of clinical consequences such as increased risk for life-threatening infections and lymphoid malignancies. Studies reported that male sex, age, family history of CLL, and CLL-susceptibility genetic loci were associated with LC MBL risk. These findings were reported in European ancestry individuals and have not been generalized to other thnicities. This study will provide this missing knowledge using a unique multi-ethnic Israeli population of Jews and Arabs that have one of the highest and lowest age-standardized incidence rates of CLL in the world, respectively, and characterized with different genetic backgrounds.

NCT ID: NCT06415474 Not yet recruiting - Clinical trials for Patients With Abdominal Infection

Evolution of the Lymphocyte Phenotype in Patients With Infection in Intensive Care Unit

REAPHEN
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Patients admitted for polytrauma, severe neurological injury, post-operative monitoring or sepsis/septic shock present with significant inflammation, leading to immunoparalysis, which is responsible for infection, particularly prolonged infection. A study of their lymphocyte phenotype over time could help explore the phenomenon of immunoparalysis.

NCT ID: NCT06412588 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication:A Prospective, Multicenter, Open-label Randomized Controlled Study.

Start date: May 2024
Phase: N/A
Study type: Interventional

It is planned to select Hp infection patients in a number of tertiary hospitals in Jiangsu and randomly divide them into three groups: group A is the classic group, receiving Vonoprazan 20mg, bid + amoxicillin 1.0g, bid + doxycycline 0.1g, bid + colloidal pectin bismuth 0.3g, bid and group C are double groups, respectively, receiving standard dose amoxicillin (1.0 g, bid) combined with vonorrasan dual regimen and doxycycline (0.1g, bid) combined with Vonoprazan dual regimen, the treatment course of the three groups was 14 days, and the oral dose of Vonoprazan was 20mg, bid, the eradication rate, adverse reactions, compliance and other aspects of the three groups were compared, In order to obtain a safe, efficient, economical and convenient Hp eradication program with a wider range of applications.

NCT ID: NCT06407232 Not yet recruiting - Clinical trials for Cytomegalovirus Infections

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Start date: May 2024
Phase: Phase 3
Study type: Interventional

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

NCT ID: NCT06405958 Not yet recruiting - Clinical trials for Microbial Colonization

Gut Microbiome Analysis in Organ Transplant Recipient

Start date: May 1, 2024
Phase:
Study type: Observational

The microbiome acts as an antigen and can induce signaling through receptors like TLRs and NODs. Microbial metabolites can directly act on gut cells or reach other organs systemically. Studies show that the commensal, non-pathogenic microbiota plays an important role in regulating the immune system in various ways: - Promoting differentiation of Th17 cells and ILC3 signaling to regulate IL-17A production - Influencing iNKT cell generation early in life to prevent inflammatory activities - Facilitating CD4+ T cell differentiation and balancing Th1/Th2 responses - Inducing regulatory T cells (Tregs) that promote immune homeostasis - Tregs in Peyer's patches help maintain a microbiome that supports homeostasis The microbiome influences T cells, B cells and immune homeostasis. This has implications for transplantation, where modulating the microbiome could impact the graft's acceptance by affecting the recipient's immune cells that respond to the transplant. In summary, it highlights the microbiome's role in immune regulation and the potential for leveraging this interaction therapeutically, including in the context of transplantation.

NCT ID: NCT06404307 Not yet recruiting - Clinical trials for Bacterial Infections

Self-administration in Outpatient Parenteral Antimicrobial Therapy Service

SELF-OPAT
Start date: May 2024
Phase: N/A
Study type: Interventional

Home Outpatient Parenteral Antimicrobial Treatment (Home-OPAT) is a service provided to patients that receive antibiotics via infusion but are clinically well enough to go home. A nurse will visit the patient daily to administer the antibiotics. However, the patient or a caregiver can also administer the antibiotics without the help of a nurse. This is called Self-OPAT. The Self-OPAT service is already in practice internationally but not yet in the Netherlands. The goal of this observational study is to assess the possibility to implement Self-OPAT in the Dutch context. The main questions it aims to answer are: Which patients are suitable for Self-OPAT services? How can patients be trained adequately for performing Self-OPAT? What are the experiences of patients with Self-OPAT? How much nurse engagement is needed during Self-OPAT? Is the outcome of treatment with Self-OPAT comparable to Home-OPAT? How do the costs of Self-OPAT differ from the costs of Home-OPAT? How can you implement an Self-OPAT program in the hospital? Participants will be trained by a nurse to administer the infusion antibiotics. They will then administer the antibiotics themselves for as long as the duration of treatment. Every week a nurse will visit to check the progression of the treatment and check the functioning and hygiene of the infusion materials. After a month participants will fill-out a questionnaire about their experience with Self-OPAT.

NCT ID: NCT06402292 Not yet recruiting - Infections Clinical Trials

Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute

Start date: September 1, 2024
Phase: N/A
Study type: Interventional

This prospective research project aims to evaluate the effectiveness and clinical outcomes of utilizing antibiotic-impregnated bioactive bone substitute (PerOssal®) in the surgical management of osteoarticular infections. Osteoarticular infections pose significant challenges in orthopaedic surgery due to the risk of persistent infection, bone loss, and functional impairment. Traditional treatment approaches involve extensive debridement followed by systemic antibiotic therapy and bone grafting. However, antibiotic-impregnated bioactive bone substitutes offer a promising alternative by providing local antibiotic delivery and promoting bone regeneration simultaneously. This study will prospectively enrol patients undergoing surgical intervention for osteoarticular infections and assess their clinical outcomes, including infection resolution, bone healing, functional recovery, and complication rates. Comprehensive data collection will include preoperative patient characteristics, intraoperative details, postoperative outcomes, and long-term follow-up assessments. Statistical analyses will be performed to compare outcomes between patients treated with antibiotic-impregnated bioactive bone substitute and those past managed with traditional methods. The findings of this study are expected to contribute valuable insights into the effectivennes and safety of this novel approach, potentially informing future clinical practices and optimizing patient care in the management of osteoarticular infections.

NCT ID: NCT06400394 Not yet recruiting - Clinical trials for Surgical Site Infection

Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution: A Randomised Double-Blind, Placebo-controlled Trial

Plasso 2
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This is randomised double blinded placebo-controlled parallel-group study. Patients in Hospital Queen Elizabeth, Sabah and Hospital Universiti Sains Malaysia, Kelantan who undergo laparotomy for peritonitis will be equally randomised into two groups : intervention group receiving super-oxidised solution and the control group receiving normal saline during peritoneal and wound lavage. This is a superiority study assessing the effectiveness of the intervention. The patient and doctors directly involved in the partient care will be blinded in this study